Literature DB >> 25578604

Epigenetic mechanisms of melatonin action in human SH-SY5Y neuroblastoma cells.

Yi Pan1, Lennard P Niles2.   

Abstract

We have shown that melatonin induces histone hyperacetylation in vitro and in vivo. To clarify the mechanisms involved, we have now investigated its effects on histone acetylation and signaling pathways in human SH-SY5Y neuroblastoma cells, which express melatonin MT1 receptors. Melatonin caused significant concentration-dependent increases in both histone H3 and H4 acetylation. Blockade of melatonin receptors with luzindole abolished the histone hyperacetylating effect of melatonin, whereas inhibition of MAPK-ERK by PD98059 attenuated but did not block this effect. Melatonin treatment for 24-h decreased the levels of phospho-ERK1/2, but significantly increased Akt phosphorylation and protein expression of the histone acetyltransferase, p300. These findings suggest that the epigenetic effects of melatonin in SH-SY5Y cells are mediated by G protein-coupled MT1 melatonin receptors. Furthermore, upregulation of the histone acetyltransferase/transcriptional co-activator p300, along with phosphorylation of Akt, which is essential for p300 activation, appear to be key mechanisms underlying the epigenetic effects of melatonin.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Epigenetic; Histone hyperacetylation; Melatonin MT(1) receptor; Phospho-Akt; p300

Mesh:

Substances:

Year:  2015        PMID: 25578604     DOI: 10.1016/j.mce.2015.01.003

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  8 in total

Review 1.  The Prospective Application of Melatonin in Treating Epigenetic Dysfunctional Diseases.

Authors:  Seth Mikaye Monayo; Xin Liu
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

Review 2.  Epigenetic regulation of melatonin receptors in neuropsychiatric disorders.

Authors:  Sarra G Bahna; Lennard P Niles
Journal:  Br J Pharmacol       Date:  2017-10-25       Impact factor: 8.739

3.  Evaluation of cell death pathways initiated by antitumor drugs melatonin and valproic acid in bladder cancer cells.

Authors:  Siwei Liu; Bilin Liang; Huiting Jia; Yuhan Jiao; Zhongqiu Pang; Yongye Huang
Journal:  FEBS Open Bio       Date:  2017-04-27       Impact factor: 2.693

4.  Melatonin enhances sorafenib actions in human hepatocarcinoma cells by inhibiting mTORC1/p70S6K/HIF-1α and hypoxia-mediated mitophagy.

Authors:  Néstor Prieto-Domínguez; Carolina Méndez-Blanco; Sara Carbajo-Pescador; Flavia Fondevila; Andrés García-Palomo; Javier González-Gallego; José L Mauriz
Journal:  Oncotarget       Date:  2017-08-24

5.  Proteasomal degradation of the histone acetyl transferase p300 contributes to beta-cell injury in a diabetes environment.

Authors:  Lucie Ruiz; Tatyana Gurlo; Magalie A Ravier; Anne Wojtusciszyn; Julia Mathieu; Matthew R Brown; Christophe Broca; Gyslaine Bertrand; Peter C Butler; Aleksey V Matveyenko; Stéphane Dalle; Safia Costes
Journal:  Cell Death Dis       Date:  2018-05-22       Impact factor: 8.469

Review 6.  Mechanisms Underlying Tumor Suppressive Properties of Melatonin.

Authors:  Stephen C Bondy; Arezoo Campbell
Journal:  Int J Mol Sci       Date:  2018-07-27       Impact factor: 5.923

Review 7.  Melatonin and neuroblastoma: a novel therapeutic approach.

Authors:  Mohammad Hossein Pourhanifeh; Mahboobeh Kamali; Saeed Mehrzadi; Azam Hosseinzadeh
Journal:  Mol Biol Rep       Date:  2021-06-01       Impact factor: 2.316

Review 8.  Promising Antineoplastic Actions of Melatonin.

Authors:  Gaia Favero; Enrico Moretti; Francesca Bonomini; Russel J Reiter; Luigi Fabrizio Rodella; Rita Rezzani
Journal:  Front Pharmacol       Date:  2018-10-16       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.